GSK & Cambridge Develop Drugs for Disease

News Medical has reported that a new collaboration between the University of Cambridge and GSK will aim to discover and develop new medicines to treat liver disease.

The collaboration with GSK will combine Professor Lomas’ long-term research at the University of Cambridge Institute for Medical Research (CIMR) with GSK’s expertise in drug discovery and development in order to develop new therapeutics. Work on the project will be carried out both at GSK and at the CIMR.

This new partnership will build upon the work of researchers who have identified a molecular mechanism that plays a major role in the life-threatening liver disease that develops in patients with a particular mutant gene.

Alpha-1 antitrypsin (A1AT) deficiency is one of the most common genetic disorders in the UK, affecting approximately one in 2,000 people. Professor Lomas said that “Currently, the only option for patients with liver disease as a result of alpha-1 antitrypsin deficiency is transplantation…….This partnership brings together our collective expertise in target biology and drug discovery to tackle an unmet medical need and by teaming up with GSK, we have a great opportunity to turn our research into effective treatments”


Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.

Posted in: Industry News, News
CK Logo in place of featured image